

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Publication of Annual Report and Accounts for the year ended 31 January 2025

Notice of Annual General Meeting

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering specialist neonatal intensive care medical devices, announces that the Annual Report and Accounts for the year ended 31 January 2025 and the notice of its Annual General Meeting ("AGM") have been published on the Company's website at www.inspirationhealthcaregroup.com and will be posted to shareholders later today.

AGM and voting

The AGM of Inspiration Healthcare will be held at 12:00 p.m. (UK time) on 24 July 2025 at the Company's registered office, Unit 7/8 Commerce Park, Commerce Way, Croydon, England, CR0 4YL.

Voting by proxy

Shareholders will not receive a hard copy form of proxy for the AGM in the post. Instead, shareholders will be able to appoint a proxy electronically via the Investor Centre app or web browser at <https://uk.investorcentre.mpms.mufig.com/>, shareholders will need to log into your Investor Centre account or register if that shareholder has not previously done so. To register, shareholders will need an Investor Code, this is detailed on your share certificate or available from our Registrars, MUFG Corporate Markets. Proxy votes must be received by no later than 12.00 pm on 22 July 2025. Alternatively, shareholders may submit a proxy vote via CREST where applicable. Shareholders who are an institutional investor may also be able to appoint a proxy electronically via the Proxymity platform (more information can be found in the notice of meeting).

Request a hard copy form of proxy

You may request a hard copy form of proxy directly from the Registrars by emailing MUFG Corporate Markets at shareholderenquiries@cm.mpms.mufig.com. Alternatively, you can request a hard copy proxy card by calling MUFG Corporate Markets on 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable International rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

For further information, please contact:

Inspiration Healthcare Group plc
Raffi Stepanian, Chief Executive Officer
Alan Olby, Chief Financial Officer

Tel: +44 (0)330 175 0000

Panmure Liberum (Nominated Adviser & Broker)
Will Goode
Emma Earl
Will King

Tel: +44 (0)20 3100 2000

Walbrook PR Ltd (Media & IR)
Anna Dunphy
Rachel Broad

Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
Mob: +44 (0) 7876 741 001

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its Manufacturing and Technology Centre in Croydon, South London, and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAPKNBDFBKPAD